Seattle, WANCT06442475Now EnrollingIRB Ready

Ann Arbor Stage II Follicular Lymphoma Clinical Trial in Seattle, WA

Access cutting-edge ann arbor stage ii follicular lymphoma treatment through this phase 2 clinical trial at a research site in Seattle. Study-provided care at no cost to qualified participants.

Sponsored by University of Washington

Quick Self-Assessment

See if you qualify for this Seattle location

Preparing your pre-screening questions…

Expert Care in Seattle

Access ann arbor stage ii follicular lymphoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related ann arbor stage ii follicular lymphoma treatment provided free

Apply for This Seattle Location

Check if you qualify for this ann arbor stage ii follicular lymphoma clinical trial in Seattle, WA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Seattle

    Convenient for WA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Seattle site if eligible
  4. 4Begin participation

About This Ann Arbor Stage II Follicular Lymphoma Study in Seattle

This phase II trial tests the safety, side effects and effectiveness of mosunetuzumab in treating patients with slow growing (indolent) B-cell lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.

Sponsor: University of Washington

Who Can Participate

Inclusion Criteria

18 years or older at time of signing informed consent
Capable of understanding and providing written informed consent
Histologically confirmed indolent B-cell non-Hodgkin lymphoma with no prior therapy for lymphoma. (Prior peptide-based therapeutic vaccines are allowed.) Eligible histologies include:
Follicular lymphoma (grade 1-2 or 3A)
Marginal zone lymphoma
Ann Arbor stage II-IV disease
No prior therapy for lymphoma
Have low-tumor burden disease, defined by Groupe D'Etude des Lymphomes Folliculaires (GELF) criteria:
Nodal or extranodal tumor mass \< 7 cm
Involvement of less than 3 nodal sites with a diameter \> 3 cm
No systemic or B symptoms
No splenomegaly \> 16 cm by imaging
No local risk of vital organ compression
No pleural or peritoneal serous effusions
No leukemic phase (\> 5,0000/ uL circulating lymphocytes)
No significant cytopenias defined as platelets \< 100,000/uL, hemoglobin \< 10 g/dL, or absolute neutrophil count (ANC) \< 1500/ uL
Have measurable nodal disease, including at least 1 disease site measuring at least 1.5 cm in longest dimension on CT or fludeoxyglucose F-18 (FDG)-PET, or a FDG-avid extranodal measurable site measuring at least 1.0 cm in longest dimension. Measurable disease also includes spleen size more than 13 cm in vertical length
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Creatinine clearance ≥ 50 mL/min calculated by Cockcroft-Gault equation
Total bilirubin ≤ 1.5 x the upper limit of normal (ULN), except in patients with Gilbert's syndrome who may have a total bilirubin up to ≤ 3 x ULN
Aspartate aminotransferase (AST) ≤ 3 x the ULN
Alanine aminotransferase (ALT) ≤ 3 x the ULN
Gamma glutamyl transferase (GGT) ≤ 3 x the ULN
Negative serum or urine pregnancy test within 7 days of initiating mosunetuzumab for women of childbearing potential, defined as those who have not been surgically sterilized or who have not been free of menses for at least 1 year
Fertile male and woman of childbearing potential must agree to use highly effective contraceptive methods from start of treatment to at least 3 months after the last dose of mosunetuzumab

Exclusion Criteria

History of severe allergic reaction to monoclonal antibody therapy
History of a second primary malignancy that could affect compliance with the protocol or interpretation of results except with permission of the principal investigator. Malignancies treated curatively or at low-risk of progressing at the judgment of the principal investigator (PI) may be included
Known active and uncontrolled bacterial, viral, fungal, mycobacterial, or other infection at study enrollment
Infection with human immunodeficiency virus (unless viral load is undetectable and CD4 count ≥ 200)
Positive test results for chronic hepatitis B infection (defined as positive hepatitis B surface antigen \[HbBsAg\] serology):
Patients with occult or prior hepatitis B infection (defined as positive total hepatitis B core antibody and negative HBsAg) may be included if hepatitis B virus (HBV) deoxyribonucleic acid (DNA) is undetectable at the time of screening. These patients must be willing to undergo monthly DNA testing and appropriate antiviral therapy as indicated by institutional standards
Autoimmune disease requiring active therapy
History of hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS)
Evidence of significant concurrent disease or medical condition that could interfere with the conduct of the study, or put the patient at significant risk including, but not limited to, significant cardiovascular disease (e.g., New York Heart Association class III or IV cardiac disease, unstable arrhythmias, or unstable angina) or pulmonary disease (including obstructive pulmonary disease and history of bronchospasm)
Ongoing systemic corticosteroid treatment, with the exception of corticosteroid use for other (non-tumor and non-immunosuppressive) indications up to a maximum of 10 mg/day of prednisone or equivalent
Prior use of any monoclonal antibody within 4 weeks before the first mosunetuzumab administration
Prior solid organ transplantation
Pregnant or breast-feeding women, or intending to become pregnant during the study or within 3 months of the last dose of mosunetuzumab

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Seattle?

Yes, this clinical trial (NCT06442475) has an active research site in Seattle, WA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Ann Arbor Stage II Follicular Lymphoma Treatment Options in Seattle, WA

If you're searching for ann arbor stage ii follicular lymphoma treatment options in Seattle, WA, this clinical trial (NCT06442475) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Seattle research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced ann arbor stage ii follicular lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all ann arbor stage ii follicular lymphoma clinical trials near you to find additional studies recruiting in your area.

More Lymphoma Trials in Seattle, WA

See all lymphoma clinical trials recruiting in Seattle — not just this study.

Browse Lymphoma Trials in Seattle →

Browse More Trials by Condition

Lymphoma TrialsFollicular Lymphoma TrialsPulmonary Hypertension TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Seattle?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Seattle, WA